FDA approves Roche's COBAS AmpliPrep / COBAS TaqMan HBV Test v2.0 ...
<a href="http://enterprisepost.com/biomed/2010/10/11" title="Weight loss pill off shelves due to heart attack risk, “Black Death” of the Middle ages blamed on bacteria, Some herbal remedies for anxiety disorders effective, Bathing better than pethidine as pain relief during labor: Survey, Meridia – weight loss pill off the shelves in US, Study finds monarch butterflies use medicinal plants to treat offspring for disease, UT Southwestern study to determine whether leptin helps type 1 diabetes patients, When in Rome: Study-abroad students increase alcohol intake, Insurance and [more...]
Date: 2010-09-23 08:41:17
Virology Journal | Full text | Serological and molecular ...
HBV DNA was detected and quantified by Real-time PCR using the commercial test from Roche Diagnostics (COBAS TaqMan HBV test) in all patients and controls positive for HBsAg and those isolated HBcAb. Statistical analysis A descriptive analysis for the data was carried out. The quantitative variables were described by mediane (md) and interquartile range (RI) if the data did not follow a normal distribution and for the categorical variables the percentages were calculated. The chi-square test was used to compare qualitative variables, while T test or ANNOVA and the corresponding [more...]
Date: 2010-10-05 23:03:45
•This is the first choice of treatment for many people with HBV infection that is likely to progress, as indicated by lab test results. •It works best in people who have relatively low levels of HBV DNA but liver function tests and liver biopsy show that the liver is affected. •Interferon usually is not given to people whose liver damage has progressed to cirrhosis, because it can make the damage worse. •Treatment is shorter than the other medications, but requires regular shots (injections) and is more expensive than the others. The older forms of interferon are given 3 or more [more...]
Date: 2010-10-06 23:39:04
Ginseng Guide and Information - Ginseng Gingkgo Biloba » Treating ...
Treating chronic mutational hepatitis B with Chinese medicine Vitalliver (Vigconic suppositories) ZHANG GUAN HUA, LIANG CHAO, ZHENG WAN PIN Chengdu University of TCM, Hepatitis Laboratory in the attached hospital of Chengdu University of TCM, Sichuan, China Research Method: Quantitative determination by contrasting HBV-DNA of cases before and after the treatment. Treating chronic mutational hepatitis B with Chinese medicine Vitalliver (Vigconic suppositories) ZHANG GUAN HUA, LIANG CHAO, ZHENG WAN PIN Chengdu University of TCM, Hepatitis Laboratory in the attached hospital of Chengdu [more...]
Date: 2003-08-17 07:00:00
Seroprevalence of Hepatitis B and C virus in HIV-1 and HIV-2 ...
© 2010 Jobarteh et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. AbstractBackground The prevalence of HIV/hepatitis co-infection in sub-Saharan Africa is not well documented, while both HIV and HBV are endemic in this area. Objective The aim of this study is to determine the seroprevalence of HBV and HCV virus in HIV-infected [more...]
Date: 2010-09-15 00:00:00
Hepatitis B, Chronic Clinical Trial: An Open Label, Multi Centre ...
An Open Label, Multi Centre Phase IV Study of Adefovir Dipivoxil in Korean Patients With Chronic Hepatitis B (CHB) Objective(s) The primary study objective is to assess the antiviral effect of 12 weeks of adefovir dipivoxil treatment in Korean patients with chronic hepatitis B and compensated liver disease. The secondary study objectives are to assess the antiviral effect, clinical benefit and safety of 52 weeks of adefovir dipivoxil treatment. Endpoint(s) The primary efficacy endpoint is "Mean log10... Date First Received: September 17, 2010 Last Updated: September 17, 2010 Verified by: [more...]
Date: 2010-09-17 04:00:00
FDA Approves Roche's Hepatitis B Viral Load Test | InfoGrok
The new Roche test provides a fully automated solution for the quantitative detection of hepatitis B virus (HBV) DNA in human plasma or serum for patients on HBV antiviral therapy. The Roche COBAS AmpliPrep / COBAS TaqMan HBV Test v2.0 has been validated to quantify diverse samples from genotypes A-H and pre-core mutants across a broad linear dynamic range of 20 IU/mL to 1.7E+08 IU/mL. The new assay uses a reduced sample input volume of 650 uL of either serum or plasma specimens and is standardized against the World Health Organization (WHO) standard for hepatitis B. This test is designed for [more...]
Date: 2010-09-23 14:10:06
Virology Journal | Full text | Anti-hepatitis B core antigen ...
Kleinman SH, Kuhns MC, Todd DS, Glynn SA, McNamara A, Di Marco A, Busch MP: Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion 2003 , 43:696-704. PubMed Abstract | Publisher Full Text Ikeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, Yamashita Y, Kudo M, Sato T, Chiba T: Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: A prospective study. Ann Intern Med 2007 , 146:649-656. PubMed Abstract Pollicino T, Squadrito G, [more...]
Date: 2010-08-27 08:43:59